Our investigational process to restore kidney function begins when a small biopsy of the diseased kidney is sent to our laboratory. We identify the patient’s healthy cells and formulate them into a personalized cell therapy product that is then re-injected into the damaged kidney to assess whether the investigational cell therapy can repair damaged tissue and / or restore kidney function.
To date, clinical studies suggest that treatment with REACT in patients with type 2 diabetes and CKD may positively impact renal function by stabilizing eGFR or attenuating the rate of eGFR decline. Preclinical studies indicate that REACT may migrate throughout the kidney, resulting in an improvement in renal function and histologic structure, including decreased interstitial fibrosis and inflammation.